Contract research organizations (CRO) are embracing a new wave of tools and approaches that are transforming how clinical trials are conducted. From leveraging artificial intelligence to designing decentralized trials, these advancements are leading to more efficient, data-driven, and patient-centric research.
Decentralized clinical trials (DCTs) are transforming the CRO industry by utilizing telemedicine, wearables and electronic patient-reported outcomes (ePRO) to enable remote participation and continuous data collection. This approach improves data quality, boosts patient involvement and cuts costs by reducing logistical barriers. DCTs enhance the patient experience and promise a more inclusive, efficient future for clinical research as these technologies advance.
Another technological trend is Generative AI transforming drug discovery and reshaping R&D with ML and NLP algorithms. It accelerates clinical trials, predicts bioactivity and toxicity, and guides drug development for cancer, Alzheimer’s, arthritis, fibrosis, and rare diseases. Various firms, including CROs, CDMOs, and leading pharma companies, are leveraging GenAI to pioneer advancements in drug development.
Driven by these trends, the global CRO market is projected to grow to approximately $118.81 billion by 2033, with a CAGR of 6.92 percent.
This edition of the Pharma Tech Outlook offers insights into the latest trends in pharmaceutical technology and how companies are aligning with these trends. Stay informed as industry leaders share their experiences and strategies for navigating the evolving landscape of healthcare technology standards and the growing demand for more user-friendly practices.
The magazine features a thought-provoking article from Chow Woai Sheng, Vice President of Global Instrument Manufacturing and Singapore General Manager of Agilent Technologies. He sheds light on pharmaceutical manufacturers boosting competitiveness and resilience amid global crises by adopting large-scale 4IR technologies for smarter, sustainable production. It also includes an article by Michael Shim, National Director of Medical Affairs at Syneos Health, Larry Dollar, Vice President Medical Affairs at Syneos Health and Drew Beck, Head of Strategy, Growth, and Innovation at Syneos Health.
In this edition of Pharma Tech Outlook, we also feature the Top CROs 2024 We hope you find the right partner to meet your organization’s needs.
